Amendmentand Responseto non-final
`Office Action dated May 11, 2018
`U.S. Patent Application No. 15/353,899
`Attorney Docket No. 046483-6001US 14(01102)
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims will replace all prior versions, andlistings, of claims in the
`
`application.
`
`1. (Previously presented) A human memory T cell comprising a nucleic acid sequence that
`
`encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen
`
`binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta
`
`signaling domain, wherein the human memory T cell is of a human having cancer.
`
`2. (Previously presented) The human memoryTcell of claim 1, wherein the CD19 antigen
`
`binding domain is a Fab or scFv.
`
`3. (Previously presented) The human memoryTcell of claim 2, wherein the CD19 antigen
`
`binding domain is a scFv.
`
`4. (Currently amended) The human memoryTcell of claim 1, wherein the transmembrane
`
`domain comprises a CD8 transmembrane domain.
`
`5. (Previously presented) The human memoryTcell of claim 1, wherein the co-stimulatory
`
`signaling region is CD27 or 4-1BB.
`
`6. (Previously presented) The human memory T cell of claim 1, wherein the CAR further
`
`comprises a hinge region.
`
`7. (Previously presented) The human memoryTcell of claim 6, wherein the hinge region
`
`comprises a CD8«a hingeregion.
`
`24933851.1 11/13/2018
`
`UPenn Ex. 2030
`
`Miltenyi v. UPenn
`IPR2022-00853
`
`UPenn Ex. 2030
`Miltenyi v. UPenn
`IPR2022-00853
`
`
`Office Action dated May 11, 2018
`U.S. Patent Application No. 15/353,899
`Attorney Docket No. 046483-6001US 14(01102)
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims will replace all prior versions, andlistings, of claims in the
`
`application.
`
`1. (Previously presented) A human memory T cell comprising a nucleic acid sequence that
`
`encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen
`
`binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta
`
`signaling domain, wherein the human memory T cell is of a human having cancer.
`
`2. (Previously presented) The human memoryTcell of claim 1, wherein the CD19 antigen
`
`binding domain is a Fab or scFv.
`
`3. (Previously presented) The human memoryTcell of claim 2, wherein the CD19 antigen
`
`binding domain is a scFv.
`
`4. (Currently amended) The human memoryTcell of claim 1, wherein the transmembrane
`
`domain comprises a CD8 transmembrane domain.
`
`5. (Previously presented) The human memoryTcell of claim 1, wherein the co-stimulatory
`
`signaling region is CD27 or 4-1BB.
`
`6. (Previously presented) The human memory T cell of claim 1, wherein the CAR further
`
`comprises a hinge region.
`
`7. (Previously presented) The human memoryTcell of claim 6, wherein the hinge region
`
`comprises a CD8«a hingeregion.
`
`24933851.1 11/13/2018
`
`UPenn Ex. 2030
`
`Miltenyi v. UPenn
`IPR2022-00853
`
`UPenn Ex. 2030
`Miltenyi v. UPenn
`IPR2022-00853
`
`
`
`Amendmentand Responseto non-final
`Office Action dated May 11, 2018
`U.S. Patent Application No. 15/353,899
`Attorney Docket No. 046483-6001US 14(01102)
`
`8. (Previously presented) A human memory T cell comprising a chimeric antigen receptor
`
`(CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane
`
`domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the
`
`human memory T cell is of a human having cancer.
`
`9. (Previously presented) The human memoryTcell of claim 8, wherein the CD19 antigen
`
`binding domain is a Fab or scFv.
`
`10. (Previously presented) The human memoryTcell of claim 9, wherein the CD19 antigen
`
`binding domain is a scFv.
`
`11. (Currently amended) The human memoryTcell of claim 8, wherein the transmembrane
`
`domain comprises a CD8 transmembrane domain.
`
`12. (Previously presented) The human memory T cell of claim 8, wherein the co-stimulatory
`
`signaling region is CD27 or 4-1 BB.
`
`13. (Previously presented) The human memory T cell of claim 8, wherein the CAR further
`
`comprises a hinge region.
`
`14. (Previously presented) The human memoryTcell of claim 13, wherein the hinge region
`
`comprises a CD8«a hingeregion.
`
`15. (Currently amended) A persisting population of human T cells comprising a nucleic acid
`
`sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a
`
`CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region
`
`and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human
`
`having cancer and when administered to the human,persist in the humanfor at least one
`
`month.
`
`24933851.1 11/13/2018
`
`UPenn Ex. 2030
`
`Miltenyi v. UPenn
`IPR2022-00853
`
`UPenn Ex. 2030
`Miltenyi v. UPenn
`IPR2022-00853
`
`
`
`Amendmentand Responseto non-final
`Office Action dated May 11, 2018
`U.S. Patent Application No. 15/353,899
`Attorney Docket No. 046483-6001US 14(01102)
`
`16. (Previously presented) The persisting population of humanTcells of claim 15, wherein
`
`the CD19 antigen binding domainis a Fab or scFv.
`
`17. (Previously presented) The persisting population of humanTcells of claim 16, wherein
`
`the CD19 antigen binding domainis a scFv.
`
`18. (Currently amended) The persisting population of human T cells of claim 15, wherein
`
`the transmembrane domain comprises a CD8 transmembrane domain.
`
`19. (Previously presented) The persisting population of human T cells of claim 15, wherein
`
`the co-stimulatory signaling region is CD27 or 4-1BB.
`
`20. (Previously presented) The persisting population of human T cells of claim 15, wherein
`
`the CAR further comprises a hinge region.
`
`21. (Previously presented) The persisting population of human T cells of claim 20, wherein
`
`the hinge region comprises a CD8a hinge region.
`
`22. (Currently amended) A persisting population of human T cells comprising a chimeric
`
`antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a
`
`transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain,
`
`wherein the persisting population of T cells are of a human having cancer_and when
`
`administered to the human, persist in the human for at least one month.
`
`23. (Previously presented) The persisting population of human T cells of claim 22, wherein
`
`the CD19 antigen binding domainis a Fab or scFv.
`
`24933851.1 11/13/2018
`
`UPenn Ex. 2030
`
`Miltenyi v. UPenn
`IPR2022-00853
`
`UPenn Ex. 2030
`Miltenyi v. UPenn
`IPR2022-00853
`
`
`
`Amendmentand Responseto non-final
`Office Action dated May 11, 2018
`U.S. Patent Application No. 15/353,899
`Attorney Docket No. 046483-6001US 14(01102)
`
`24. (Previously presented) The persisting population of human T cells of claim 23, wherein
`
`the CD19 antigen binding domainis a scFv.
`
`25. (Currently amended) Thepersisting population of human T cells of claim 22, wherein
`
`the transmembrane domain comprises a CD8 transmembrane domain.
`
`26. (Previously presented) The persisting population of human T cells of claim 22, wherein
`
`the co-stimulatory signaling region is CD27 or 4-1BB.
`
`27. (Previously presented) The persisting population of human T cells of claim 22, wherein
`
`the CAR further comprises a hinge region.
`
`28. (Previously presented) The persisting population of humanTcells of claim 27, wherein
`
`the hinge region comprises a CD8a hinge region.
`
`24933851.1 11/13/2018
`
`UPenn Ex. 2030
`
`Miltenyi v. UPenn
`IPR2022-00853
`
`UPenn Ex. 2030
`Miltenyi v. UPenn
`IPR2022-00853
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
